Table of Content

1. Introduction To CD40 Targeted Therapies
1.1 Overview
1.2 Considering CD40 As Drug Target Over Other CD Markers
1.3 History & Evolution Of CD40 Targeting Therapies


2. CD40 Targeted Therapies – Mechanism Of Action
2.1 Agonist Mediated Activation Of CD40 Signaling
2.2 Antagonist-Mediated Inhibition Of CD40 Signaling


3. CD40 Targeted Therapeutic Approaches
3.1 Antibody Formats
3.2 Fusion Proteins
3.3 Peptides
3.4 Nucleic Acids


4. CD40 Targeted Therapy Research & Development Trends By Indication
4.1 Cancer
4.2 Neurological Diseases
4.3 Autoimmune & Inflammatory Disorders
4.4 Transplant Rejection
4.5 Microbial Infections


5. Global CD40 Targeted Therapy Market Outlook
5.1 Current Market Trends & Developments
5.2 Future Market Opportunities


6. CD40 Targeted Therapy Market Trend Analysis By Region
6.1 US
6.2 Europe
6.3 China

6.4 Japan
6.5 Australia


7. CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase III


8. CD40 Targeted Therapies - Proprietary Technologies By Company
8.1 Alligator Bioscience - FIND Technology & Neo-X-Prime
8.2 Aprilbio - SAFA Platform
8.3 Biocytogen – RenMice
8.4 EnnoDC – Unnamed Platform
8.5 Genmab – DuoBody
8.6 Harbour BioMed - Harbour Mice & HBICE
8.7 Kyowa Kirin – REGULGENT
8.8 Strike Pharma - ADAC Technology Platform


9. Global CD40 Targeted Therapy Market Dynamics
9.1 Drivers & Opportunities
9.2 Challenges & Restraints


10. Competitive Landscape
10.1 Alligator Bioscience
10.2 Amgen
10.3 Biogen
10.4 BioNTech
10.5 Eledon Pharmaceuticals
10.6 EnnoDC
10.7 Genmab
10.8 Innovent Bio
10.9 Novartis
10.10 Sanofi
10.11 Tonix Pharmaceuticals
10.12 UCB



List of Figures

Figure 1-1: CD40 – Salient Features
Figure 1-2: CD40 Targeted Therapy Landscape – Major Milestones

Figure 2-1: CD40 Agonists – Mechanism of Action

Figure 3-1: Prominent Antibody Formats for Targeting CD40

Figure 4-1: OPTIMIZE-1 Phase 1b/2 (NCT04888312) Study – Initiation & Completion Year
Figure 4-2: Mitazalimab Phase 1 (NCT06205849) Study – Initiation & Completion Year
Figure 4-3: 2141-V11 Phase 1/2 (NCT05126472) Study – Initiation & Completion Year
Figure 4-4: 2141-V11 Phase 1 (NCT06455605) Study – Initiation & Completion Year
Figure 4-5: 2141-V11 Phase 1/2 (NCT05734560) Study – Initiation & Completion Year
Figure 4-6: ACT16877 Phase 2 (NCT04879628) Study – Initiation & Completion Year
Figure 4-7: FREVIVA Phase 3 (NCT06141486) Study – Initiation & Completion Year
Figure 4-8: FREXALT 3 (NCT06141473) Study – Initiation & Completion Year
Figure 4-9: HZNP-DAZ-301 Phase 3 (NCT06104124) Study – Initiation & Completion Year
Figure 4-10: HZNP-DAZ-303 Phase 3 (NCT06245408) Study – Initiation & Completion Year
Figure 4-11: VIBRANT Phase 2 (NCT05201469) Study – Initiation & Completion Year
Figure 4-12: CONTROL-RA Phase 2 (NCT05306353) Study – Initiation & Completion Year
Figure 4-13: PHOENYCS FLY Phase 3 (NCT06617325) Study – Initiation & Completion Year
Figure 4-14: SL0046 Phase 3 (NCT04976322) Study – Initiation & Completion Year
Figure 4-15: APB-A1 Phase 1b (NCT06557850) Study – Initiation & Completion Year
Figure 4-16: FABULINUS Phase 2 (NCT06111586) Study – Initiation & Completion Year
Figure 4-17: IRB23-1367 Phase 1/2 (NCT06111586) Study – Initiation & Completion Year
Figure 4-18: AT-1501-K102 Phase 1 (NCT05027906) Study – Initiation & Completion Year
Figure 4-19: BESTOW/AT-1501-K207 Phase 2 (NCT05983770) Study – Initiation & Completion Year
Figure 4-20: BESTOW-EXTENSION/AT-1501-K209 Phase 2 (NCT06126380) Study – Initiation & Completion Year
Figure 4-21: ANRS VRI06 Phase 1 (NCT04842682) Study – Initiation & Completion Year
Figure 4-22: HVTN 318 Phase 1 (NCT06665646) Study – Initiation & Completion Year
Figure 4-23: ANRS0407s - LKV.Cov40 Phase 1/2 (NCT06255626) Study – Initiation & Completion Year

Figure 8-1: Alligator Bioscience - FIND technology
Figure 8-2: Alligator Bioscience - Neo-X-Prime
Figure 8-3: Aprilbio - SAFA Antibody APB-A1
Figure 8-4: Genmab – DuoBody
Figure 8-5: Harbour BioMed - Harbour Mice
Figure 8-6: Harbour BioMed - HCAb
Figure 8-7: H2L2 & HCAb Platforms - Features
Figure 8-8: Harbour BioMed - HBICE
Figure 8-9: Kyowa Kirin - REGULGENT
Figure 8-10: ADAC Technology Platform - Features
Figure 8-11 Strike Pharma - ADAC Technology Platform
Figure 8-12: Strike Pharma - ADAC Molecule

Figure 9-1: CD40 Targeted Therapy Market - Drivers & Opportunities
Figure 9-2: CD40 Targeted Therapy Market - Challenges & Restraints

List of Tables

Table 5-1: CD40 Targeted Therapies in Phase III Clinical Trials

Table 7-1: CD40 Targeted Therapies in Research Stage, 2024
Table 7-2: CD40 Targeted Therapies in Preclinical Stage, 2024
Table 7-3: CD40 Targeted Therapies in Phase I, 2024
Table 7-4: CD40 Targeted Therapies in Phase I/II, 2024
Table 7-5: CD40 Targeted Therapies in Phase II, 2024
Table 7-6: CD40 Targeted Therapies in Phase III, 2024